Last updated on March 2020

A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis


Brief description of study

This is a 52 week Phase 2b study designed to evaluate the efficacy at 16 weeks and to evaluate the safety and efficacy up to 1 year in subjects with active psoriatic arthritis.

Clinical Study Identifier: NCT03963401

Find a site near you

Start Over

Emeritus Research

Camberwell, Australia
  Connect »

Cabrini Hospital

Malvern, Australia
  Connect »

BENU Lekarna

Pardubice, Czechia
  Connect »

CCR Czech a.s.

Pardubice, Czechia
  Connect »

MEDICAL PLUS s.r.o.

Uherske Hradiste, Czechia
  Connect »

Innomedica OU

Tallinn, Estonia
  Connect »

Limited Liability Company "Sanavita"

Saint Petersburg, Russian Federation
  Connect »

LLC "BioMed"

Vladimir, Russian Federation
  Connect »

REUMEX s.r.o.

Rimavska Sobota, Slovakia
  Connect »

Emeritus Research

Melbourne, Australia
  Connect »